Persistent challenges with treating multiple myeloma early.
Blood
; 137(4): 456-458, 2021 01 28.
Article
en En
| MEDLINE
| ID: mdl-33236046
ABSTRACT
Over the past decade, 2 strategies have advanced the treatment of patients with multiple myeloma and its precursor diseases. First, the definition has changed to include patients without end organ damage, who previously would not have been treated. Second, there is widespread enthusiasm for treating high-risk, smoldering multiple myeloma. In this commentary, we explore the evidence supporting these therapeutic expansions. Although early treatment adds cost and therapeutic burden, it remains unknown whether survival and health-related quality of life are improved by early treatment. Herein, we consider the implications of diagnostic expansion in multiple myeloma.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Mieloma Múltiple Quiescente
/
Mieloma Múltiple
Tipo de estudio:
Clinical_trials
/
Diagnostic_studies
/
Etiology_studies
/
Risk_factors_studies
/
Screening_studies
Límite:
Humans
Idioma:
En
Revista:
Blood
Año:
2021
Tipo del documento:
Article
País de afiliación:
Canadá